Observational studyAlimentary pharmacology & therapeutics2019
Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes.
Observational study in Alimentary pharmacology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Long-Term Risk Trajectories of Diabetes Differ After Direct-Acting Antiviral and Interferon Therapy in Chronic Hepatitis C: A Real-World Cohort Study.Biomedicines · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease After Hepatitis C Virus Cure.The Kaohsiung journal of medical sciences · 2026Review
- Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan.The Kaohsiung journal of medical sciences · 2025Article
- Impact of Direct-Acting Antivirals on Extrahepatic Manifestations in Chronic Hepatitis C: A Narrative Review with a Hermeneutic Approach.Healthcare (Basel, Switzerland) · 2025Review
- Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study).Infectious diseases and therapy · 2025Article
- Cardioprotective effect of antiviral therapy among hepatitis C infected patients: A meta-analysis.International journal of cardiology. Heart & vasculature · 2023Article
- Association between treatment of hepatitis C virus and risk of cardiovascular disease among insured patients with the virus in the United States.Pharmacoepidemiology and drug safety · 2023Article
- Effects of hepatitis C virus genotypes and viral load on glucose and lipid metabolism after sustained virological response with direct-acting antivirals.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis C Virus Infection.Biology · 2022Review
- [Evolution of clinical outcomes following hepatitis C virus clearance].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?Biomedicines · 2022Review
- Identification of key molecular markers of acute coronary syndrome using peripheral blood transcriptome sequencing analysis and mRNA-lncRNA co-expression network construction.Bioengineered · 2021Article
- The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Article
- Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population.Kidney international reports · 2021Review
- Direct antiviral agents in hepatitis C virus related liver disease: Don't count the chickens before they're hatched.World journal of gastroenterology · 2021Review
- Interleukin-6-174G/C polymorphism is associated with a decreased risk of type 2 diabetes in patients with chronic hepatitis C virus.World journal of hepatology · 2020Article
- Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.Cold Spring Harbor perspectives in medicine · 2020Review
- Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study.Internal and emergency medicine · 2020Article
- The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm.Journal of clinical medicine · 2020Review
- A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model.Statistics in medicine · 2020Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundThe role of hepatitis C (HCV) eradication on the long-term complications of type 2 diabetes mellitus remains incompletely studied.
aimTo investigate whether antiviral treatment impacted risk of acute coronary syndrome, end-stage renal disease, ischaemic stroke, and retinopathy among diabetic patients from the four US health systems comprising the Chronic Hepatitis Cohort Study (CHeCS).
methodsWe included CHeCS HCV patients with diagnosis codes for type 2 diabetes who were on antidiabetic medications. Patients were followed until an outcome of interest, death, or last health system encounter. The effect of treatment on outcomes was estimated using the competing risk analysis (Fine-Gray subdistribution hazard ratio [sHR]), with death as a competing event.
resultsAmong 1395 HCV-infected patients with type 2 diabetes, 723 (52%) were treated with either interferon-based or direct-acting antivirals (DAAs); 539 (75% of treated) achieved sustained virological response (SVR). After propensity score adjustment to address treatment selection bias, patients with SVR demonstrated significantly decreased risk of acute coronary syndrome (sHR = 0.36; P < 0.001), end-stage renal disease (sHR = 0.46; P < 0.001), stroke (sHR = 0.34; P < 0.001), and retinopathy (sHR = 0.24; P < 0.001) compared to untreated patients. Results were consistent in subgroup analyses of DAA-treated patients and interferon-treated patients, an analysis of cirrhotic patients, as well as in sensitivity analyses considering cause-specific hazards, exclusion of patients with on-treatment retinopathy, and treatment status as a time-varying covariate.
conclusionSuccessful HCV treatment among patients with type 2 diabetes significantly reduces incidence of acute coronary syndrome, end-stage renal disease, ischaemic stroke, and retinopathy, regardless of cirrhosis. Our findings support the importance of HCV antiviral therapy among patients with type 2 diabetes to reduce the risk of these extrahepatic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.